Table 3.

Ongoing clinical trials of CAR-T and TCR-T in NPC.

Trial Number	Phase	Estimated enrollment	Study Title	Interwentions	Locations
NCT03013712	Phase 1/2	60	A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer	Biological: CAR-T cell immunotherapy	China
NCT02980315	Phase 1/2	20	A New EBV Related Technologies of T Cells in Treating Malignant Tumors and Clinical Application	CAR-T cell	China
NCT02915445	Phase 1	30	EpCAM CAR-T for Treatment of Advanced Solid Tumors	Biological: EpCAM CAR-T cells	China
NCT05239143	Phase 1	100	P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects with Advanced or Metastatic Solid Tumors	Biological: P-MUC1C-ALLO1 CAR-T cells Drug: Rimiducid	United States
NCT03648697	Phase 2	20	EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC	Biological: EBV-TCR-T (YT-E001) cells	China
NCT04107142	Phase 1	10	Haplo/Allogeneic NKG2DL-targeting Chimeric Antigen Receptor-grafted γδ T Cells for Relapsed or Refractory Solid Tumour	Biological: Adoptive Cell Transfer of NKG2DL-targetting Chimeric Antigen Receptor-grafted Gamma Delta T cell	Malaysia
NCT04509726	Phase 1/2	20	LMP2-Specific IL12-secreting TCR-T Cells in the Treatment of EBV-Positive Met	Drug: LMP2 Antigen-specific TCR T cells	China
NCT03648697	Phase 2	20	EBV-TCR-T(YT-E001)for Patients With EBV-positive Recurrent or Metastatic NPC	Biological: EBV-TCR-T (YT-E001) cells	China
NCT03925896	Phase 1	27	Phase I Trial of LMP2 Antigen-specific TCR T-cell Therapy for Recurrent and Metastatic NPC Patients	Drug: LMP2 Antigen-specific TCR T cells	China
NCT05587543	Phase 1	24	Clinical Study on the EBV CAR-T/TCR-T Cells in the Treatment of Nasopharyngeal Carcinoma	Behavioral: PK Blood Collection Drug: CAR, TCR	China